OME Clinical Trials

4,286 recruitingLast updated: May 13, 2026

There are 4,286 actively recruiting ome clinical trials across 115 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


OME Trials at a Glance

4,286 actively recruiting trials for ome are listed on ClinicalTrialsFinder across 6 cities in 115 countries. The largest study group is Not Applicable with 1,508 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running ome studies include M.D. Anderson Cancer Center, Assistance Publique - Hôpitaux de Paris, and Riphah International University.

Treatments under study

About OME Clinical Trials

Looking for clinical trials for OME? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new OME trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about OME clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 4,286 trials

Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting

CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer

Colorectal Cancer (CRC)Early-onset Colorectal CancerMicrobiome
Gulbenkian Institute for Molecular Medicine400 enrolled2 locationsNCT06734156
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
University of Washington30 enrolled1 locationNCT06738368
Recruiting
Phase 1Phase 2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes
National Cancer Institute (NCI)160 enrolled1 locationNCT06303193
Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 3

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals300 enrolled2 locationsNCT07498426
Recruiting

Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease

Hypoplastic Left Heart SyndromeCongenital Heart DiseaseCyanotic congenital heart disease+1 more
Institut National de la Santé Et de la Recherche Médicale, France174 enrolled5 locationsNCT06711666
Recruiting
Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Endometrial Cancer
Canadian Cancer Trials Group393 enrolled108 locationsNCT05640999
Recruiting
Phase 1Phase 2

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06308588
Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

dry eye syndromeSystemic Lupus Erythematosus
AbbVie36 enrolled6 locationsNCT06977724
Recruiting

Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)

CancerOncologyNutrition, Healthy+2 more
Xiaoqin Luo1,538 enrolled1 locationNCT06219083
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting
Phase 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma
National Cancer Institute (NCI)255 enrolled170 locationsNCT07198074
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 2

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Myelodysplastic Syndrome
National Cancer Institute (NCI)54 enrolled140 locationsNCT06577441
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225